Clinical trials: Stage IIIB Non-Small Cell Lung Cancer
Lung Cancer
Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00117962
- Testing
- cetuximab, carboplatin, pemetrexed disodium
- Where
- 71 sites in United States
- Volunteers
- 109 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Squamous Non-Small Cell Lung Cancer
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of onartuzumab in combination with erlotinib in patients with previously untreated, unresectable stage IIIB or IV…
- Trial name
- NCT01887886
- Testing
- erlotinib, onartuzumab
- Where
- 35 sites in United States, France and 6 more
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer, Recurrent Non-Small Cell Lung Carcinoma
Yoga in Improving Quality of Life in Patients With Non-small Cell Lung Cancer Undergoing Treatment
The purpose of this research study is to evaluate the effects of yoga (including breathing exercises) on the quality of life in patients, diagnosed and undergoing standard treatments for non-small cell lung cancer.
- Trial name
- NCT02895503
- Testing
- Yoga, Support Group Therapy, FACT-L
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Virginia Commonwealth University
Breast Neoplasms, Pancreatic Neoplasms
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
The purpose of this study is to assess safety of nab-paclitaxel based chemotherapy regimens administered prior to and/or in combination with nivolumab in Pancreatic Cancer, Non Small Cell Lung Cancer (NSCLC) and Metastatic Breast…
- Trial name
- NCT02309177
- Testing
- nab-Paclitaxel, Nivolumab, Gemcitabine
- Where
- 15 sites in United States
- Volunteers
- 114 people
- Sponsor
- Celgene
Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer
This randomized clinical trial studies enhanced quitline intervention in smoking cessation for patients with non-metastatic lung cancer.
- Conditions
- Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
- Trial name
- NCT01457469
- Testing
- questionnaire administration, quality-of-life assessment, counseling intervention
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Wake Forest University Health Sciences
Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
This randomized pilot clinical trial studies exercise intervention in improving quality of life and exercise capacity and reducing inflammation and oxidative stress in patients with lung cancer and their support persons.
- Conditions
- Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01999881
- Testing
- exercise intervention, standard follow-up care, quality-of-life assessment
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Lung Cancer
Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00081302
- Testing
- cetuximab, carboplatin, paclitaxel
- Where
- United States
- Sponsor
- Radiation Therapy Oncology Group
Lung Cancer
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more…
- Trial name
- NCT00083083
- Testing
- carboplatin, cisplatin, docetaxel
- Where
- 49 sites in United States, Canada and 1 more
- Volunteers
- 250 people
- Sponsor
- American College of Radiology Imaging Network
Breast Cancer, Esophageal Cancer
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells of by stopping them from dividing.
- Conditions
- Breast Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer
- Trial name
- NCT01172028
- Testing
- Taxotere (Docetaxel), Alimta (Pemetrexed)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Arizona
Non Small Cell Lung Cancer
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
ADOPT-lung is an international, multicentre, open-label randomised phase III trial. Protocol treatment consists of 3-4 cycles of neoadjuvant durvalumab in combination with platinum-based doublet chemotherapy, followed by surgery.
- Trial name
- ADOPT-lung (NCT06284317)
- Testing
- Adjuvant durvalumab
- Where
- 42 sites in Australia, Austria and 8 more
- Volunteers
- 290 people
- Sponsor
- ETOP IBCSG Partners Foundation
NSCLC
Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
The purpose of this study is to observe and evaluate the efficacy and safety of cadonilimab combined with chemotherapy in patients with resectable IB (≥ 4cm) - IIIB (N2) stage PD-L1 negative non-small cell lung cancer
- Trial name
- NCT06532591
- Testing
- cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Lung Cancer
Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo
This study is intended for participants with advanced, not amenable to surgery, or metastatic lung cancer who have not received any prior chemotherapy.
- Trial name
- NCT00538681
- Testing
- enzastaurin, pemetrexed, cisplatin
- Where
- 12 sites in Belgium, Germany and 3 more
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
The purpose of this study is to compare gefitinib with carboplatin / paclitaxel doublet chemotherapy given as first line treatment in terms of progression free survival in selected NSCLC patients with the objective of…
- Trial name
- IPASS (NCT00322452)
- Testing
- Gefitinib, Carboplatin, Paclitaxel
- Where
- 56 sites in China, Hong Kong and 7 more
- Volunteers
- 1,329 people
- Sponsor
- AstraZeneca
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous…
- Trial name
- NCT01333007
- Where
- 152 sites in France
- Volunteers
- 423 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
The purpose of this study is to assess the efficacy of selumetinib in combination with docetaxel (75mg/m2) vs placebo in combination with docetaxel (75mg/m2) in patients with locally advance or metastatic NSCLCs that harbor…
- Trial name
- SELECT-1 (NCT01933932)
- Testing
- Selumetinib, Docetaxel, Pegylated G-CSF
- Where
- 197 sites in United States, Argentina and 24 more
- Volunteers
- 510 people
- Sponsor
- AstraZeneca
Lung Cancer
Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy
RATIONALE: Measuring changes in glucose metabolism in patients with cancer may help doctors predict how patients respond to treatment.
- Trial name
- NCT00450567
- Testing
- computed tomography, positron emission tomography, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung
Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer
Feasibility of pragmatic concomitant chemo-radiotherapy association with 1 cycle of Induction chemotherapy, weekly chemo-radiotherapy, and consolidation chemotherapy.
- Trial name
- BIB 01 (NCT00210171)
- Testing
- Toxicity : Time to progression, 1 and 2 years survival
- Where
- 7 sites in France
- Sponsor
- Institut Bergonié
Carcinoma, Non-Small-Cell Lung (NSCLC)
Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer
Neoadjuvant chemoimmunotherapy has improved outcomes in patients with resectable non-small cell lung cancer (NSCLC), but a substantial proportion of patients do not achieve a major pathological response.
- Trial name
- NEOCTATC (NCT07855965)
- Testing
- Cryo-Thermal Ablation, Toripalimab, Platinum-based doublet chemotherapy
- Where
- 9 sites in China
- Volunteers
- 40 people
- Sponsor
- West China Hospital
Non-Small Cell Lung Cancer
Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
The primary purpose of this study is to look at effects, good or bad, of combining two investigational anti-cancer drugs called MPDL3280A and CDX-1401.
- Trial name
- NCT02495636
- Testing
- CDX-1401, MPDL3280A
- Where
- United States
- Sponsor
- Yale University
Breast Cancer, Colorectal Cancer
Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
RATIONALE: Placing a gene into T cells may improve the body's ability to recognize cancer cells and build an immune response to fight cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT01212887
- Testing
- MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes, aldesleukin, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Cancer Research UK
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.